Online: | |
Visits: | |
Stories: |
Story Views | |
Now: | |
Last Hour: | |
Last 24 Hours: | |
Total: |
A promising new study finds that the medical application of this controversial but increasingly decriminalized plant may extend to helping HIV patients.
The study, published in the journal AIDS Research & Human Retroviruses, indicates that the primary psychoactive ingredient in marijuana known as tetrahydrocannabinol (THC) may be an effective agent in the treatment of HIV/AIDS.
The study used male rhesus macaques infected with simian immunodeficiency virus (SIV), a retrovirus that crossed the species barrier into humans producing HIV-1 and HIV-2, respectively.
While this article will not address in-depth the origin of the SIV-to-HIV crossover event, it should be noted that the prevailing explanation known as the ‘bushmeat’ hypothesis – crossover presumably caused by human contact with the blood of chimps hunted in Africa – overlooks several important facts: 1) SIVs have been in close contact with humans for at least 32,000 years without the emergence of HIV.[i] 2) The HIV epidemic occurred suddenly in the mid-20th century coterminous with the introduction of vaccines with the original HIV-afflicted African populations. 3) The monkey tissue based vaccine production process has already produced similar cross-over events, with millions around the world being infected with SV-40 contaminated oral polio vaccines.
Given these facts, HIV should not be classified as a zoonosis[ii] (an infectious disease transmitted between species), but a direct result of human activity, and likely biomedical intervention, specifically vaccines.[iii]